Navigation Links
Revisiting Prevention of Blood Clots in Chemotherapy Patients

Durham, NC (PRWEB) November 08, 2013

A large-scale analysis assessing the real-world risk of venous thromboembolism (VTE), commonly called blood clots, among chemotherapy patients shows a greater occurrence of VTE than identified in clinical trials, with a progressively increased risk during the year following treatment initiation. The study shows that outpatients receiving chemotherapy are at high risk of developing VTE and of major bleeding complications, especially those with pancreas, stomach and lung cancer. The authors therefore conclude that thromboprophylaxis, or blood thinning treatments, should be considered for such patients, after carefully assessing the risks and benefits of treatment.

The study, led by Gary H. Lyman, MD, at the Duke University School of Medicine and Duke Cancer Institute, in collaboration with scientists from Sanofi and King’s College Hospital in London, UK was published online this week in The Oncologist. The team of researchers hypothesized that there is a definable high-risk cohort of patients who would benefit from thromboprophylactic treatment for VTE and that the scope of this risk warrants consideration for the use of prophylaxes such as low- and ultra-low-molecular-weight heparins, which recent studies have found to be safe and effective for use in the prevention of VTE in chemotherapy patients.

The study involved a random sample of approximately 27,500 patients with high-VTE-risk cancer types (i.e., lung, pancreas, stomach, colon/rectum, bladder or ovary) who had undergone chemotherapy. The group retrospectively evaluated the patients’ VTE risk as well as their risk of bleeding and the economic burden borne by the patient as a result of the disease.

The risk of VTE increased over time, with a greater percentage of patients developing the complication at 12 months after initiation of chemotherapy than at 3 months; this held true across three definitions of VTE considered. According to definition A, the least conservative of the three, VTE was most frequently observed in cancers of the pancreas, lung, and stomach, and the overall incidence of the complication was 13.5% at a year, with no indication of plateau or tapering at that time point. Patients with VTE showed a higher risk of major bleeding events in the year following chemotherapy initiation. According to definition A, that risk was 19.8%, compared with 9.6% in patients without VTE. These rates are higher than has been reported with anticoagulation use in clinical trials, again likely reflecting how clinical claims data can be more representative of actual practice than clinical trial data. Moreover, while the baseline healthcare costs of patients who would develop VTE were comparable to those of patients who would not, the costs of the VTE patients soared over the year following chemotherapy initiation. On average, patients with VTE had $110,719 in expenses compared with $76,804 for patients without VTE, a difference primarily accounted for by VTE-related inpatient, outpatient, and emergency room expenses.

The authors discussed the fact that the incidence of VTE reported in this study is inconsistent with those previously reported for placebo groups in randomized clinical trials, which may be due to the selection of lower-risk patients for participation in these studies. “Importantly, this observational study suggests that the observed rates of symptomatic VTE in real-world practice are considerably greater than reported in patients eligible for randomized clinical trials,” said Dr. Lyman, head researcher of the study and co-chair of the recently published American Society of Clinical Oncology Guideline’s on VTE Treatment and Prevention. He added, “[The] risk continues to increase over time during the year following initial treatment.” This observation highlights the importance of using an unselected population to evaluate the true risk of a disease.

According to Dr. Lyman, “Clinical oncologists need to be aware of the increased risk of this serious complication of cancer and cancer treatment, and when the risk is sufficiently great and the balance of benefits and harms acceptable, oncologists should consider prophylactic anticoagulation.”

Lecia V. Sequist, MD, Deputy Editor of The Oncologist adds, “This report illustrates the frequency, complications and costs of blood clots in everyday clinical practice. While prophylactic anticoagulation during chemotherapy is not currently recommended, the authors demonstrate inherent shortcomings in studying selected patients on clinical trials. Ideally, future studies on this issue will be able to better approximate the real world, and most importantly identify the patients at highest risk for subsequent VTE.”


The full article, titled “Venous Thromboembolism Risk in Patients with Cancer Receiving Chemotherapy: A Real-World Analysis,” can be accessed at

About The Oncologist
Established by oncologists to help physicians better manage their practices in an ever-changing environment, The Oncologist® is the official journal of the Society for Translational Oncology (STO). Now in its 18th year, this internationally peer-reviewed journal focuses on clear and concise interpretation addressing the multimodality diagnosis, treatment, and quality of life of the cancer patient. Each issue is meant to impact the practice of oncology and to facilitate significant communication in the introduction of new medical treatments and technologies. For more information, visit

About AlphaMed Press: Established in 1983, AlphaMed Press, with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® (, which celebrated its 31st year in 2013, is the world's first journal devoted to this fast paced field of research. THE ONCOLOGIST® (, entering its 18th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE® (, in its second year, is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scientists at Cancer Prevention Institute of California Find That a Diet High in Fruits and Vegetables May Significantly Reduce Risk of Breast Cancer
2. ‘Path to 2025’ Alzheimer’s Disease Summit: Reforms Urgently Needed to Streamline Road to Alzheimer’s Prevention and Treatment as Global Prevalence is Set to Triple
3. Study Finds Infants Under 6 Months Too Young for Flu Shot at High Risk to Influenza Fatalities- UV Technologies Makers of UV-Aid, Develop New Flu Prevention Alternative
4. Miami-Based Bullying Prevention Organization Partner with Organization Committed to Lasting Solutions through Communication to Offer Solutions to Miami Dolphins
5. Brock Educational Seminar Brings Experts in Injury Prevention, Sustainability and Landscape Design Together to Discuss Building Safer, More Eco-effective Playing Fields
6. New IOF review provides guidance on fracture prevention in cancer-associated bone disease
7. Dr. Laurence C. Breiterman Raises Awareness of Gum Disease Prevention for Dental Hygiene Awareness Month This October in Wayne, NJ
8. Evaluation of hospital infection prevention policies can identify opportunities for improvement
9. PharmaFocus: HIV - R&D Strategies towards Cure and Prevention
10. Stroke prevention surgery less effective than meds, lifestyle change
11. IPM receives 2 awards from USAID to advance HIV prevention technologies for women
Post Your Comments:
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: